Sun Pharm acquires rights to trademarks of 3 diabetes drug brands in India from AstraZeneca
28th May 2021

Sun Pharma has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India with effect from May 28, 2021. The company has also taken a patent license to manufacture and commercialise Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from May 28, 2021.

Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for distribution of Dapagliflozin.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.